The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
The Neurotoxicity of Drugs Given Intrathecally (Spinal)
Abstract
A growing understanding of the neuropharmacology of spinal cord processing of nociceptive input has led to intense interest in the use of spinal drugs in anesthesia and pain management. The direct application of receptor-specific therapeutics at the spinal cord can potentially interrupt specific pain pathways and limit systemic side effects, but this practice also carries the inherent risk of injury to the central nervous system. Thus, the neurotoxicity of spinal drugs is a central safety issue. Spinal cord or nerve root toxicity may manifest itself as histologic, physiologic, or behavioral/clinical derangements after exposure to a spinal drug. Neurohistopathology is broadly classified as neural injury, gliosis, or damage to the myelin sheath, and it also describes inflammatory changes and involvement of the arachnoid cell layers. Physiologic neurotoxicity of spinal drugs includes changes in spinal cord blood flow, disruption of the blood-brain barrier, and changes in the electrophysiology of impulse conduction. Behavioral and clinical signs of neurotoxicity include pain, motor and sensory deficits, and bowel and bladder dysfunction. Ideally, a complete roster of histological, physiologic, and behavioral testing would be performed on spinal drugs in several animal species, followed by safety trials in humans before widespread use. In practice, drugs have taken a variety of roads from conception to application, and often without safety data. In this article, we review available neurotoxicity data on drugs that have a clinical application, classified as spinal local anesthetics, spinal analgesics, or spinal adjuvants. Spinal Local Anesthetics The 100-yr history of spinal local anesthetic use in humans has typically involved self-experimentation, followed by widespread application with little or no controlled testing for neurotoxicity. Bier and Hildebrant [1] initially performed spinal anesthesia with cocaine on themselves in 1898, and essentially all of the earliest local anesthetics for spinal anesthesia were introduced in this fashion without toxicity studies. Despite a long history of clinical use, recent interest in neurotoxicity has arisen due to concerns over reports of cauda equina syndrome and transient neurologic symptoms (TNS) from spinal local anesthetics. We review animal data that have been used to assess the neurotoxicity of local anesthetics and summarize data available from human studies. In 1985, Ready et al. [2] evaluated the neurotoxic effects of single injections of local anesthetics in rabbits. They reported that spinal cord histopathology remained normal and that persistent neurologic deficits were not seen with clinically used concentrations of tetracaine, lidocaine, bupivacaine, or chlorprocaine. However, histopathologic changes and neurologic deficits did occur with higher concentrations of tetracaine (1%) and lidocaine (8%). In this model, extensive neurologic impairment was not necessarily accompanied by equally extensive lesions in the spinal cord and nerve roots, thus demonstrating the need for multiple models to fully assess neurotoxicity. Recent studies have used desheathed peripheral nerve models, designed to mimic unprotected nerve roots in the cauda equina, to further assess electrophysiologic neurotoxicity of clinically relevant concentrations of local anesthetics [3-5]. These models demonstrate that clinically used concentrations of 5% lidocaine and 0.5% tetracaine cause irreversible conduction block, whereas 1.5% lidocaine, 0.75% bupivacaine, and 0.06% tetracaine do not. Electrophysiologic toxicity of lidocaine in these models is concentration-dependent (Figure 1) beginning at 40 mM (approximately 1%) with irreversible ablation of the compound action potential at 80 mM (approximately 2%). Kanai et al. [4] subsequently demonstrated that generation of action potentials was more vulnerable than maintenance of resting membrane potential and that irreversible ablation of action and resting membrane potential by lidocaine seems to be both concentration- and time-dependent.Figure 1: The nonreversible effect of 40 mM lidocaine on the compound action potential (CAP) of frog sciatic nerve. Lidocaine was applied to a stable nerve preparation for 15 min, then washed with frog Ringer's solution for 2 h. Tracings represent CAPs in response to stimuli (1-Hz stimulus = heavy line, 40-Hz stimulus = thin line). Lidocaine 40 mM completely ablated the CAP when applied to the nerve. The 1-Hz CAP response began to return after 10-15 min of washing and reached a new level in 45 min, where it was stable for the subsequent 2 h of observation. The recovered 1-Hz CAP is only 65% of the original. Reprinted with the publisher's permission from Holman SJ. Anesthesiology: hyperbaric dye solution distribution. Anesthesiology 1997;86:969.Effects of local anesthetics on spinal cord blood flow seem benign. Spinal administration of bupivacaine, lidocaine, mepivacaine, and tetracaine causes vasodilation and i
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Serious Complications Related to Regional Anesthesia: Results of a Prospective Survey in France
Auroy, Y., Narchi, P., Messiah, A., Litt, L., Rouvier, B., & Samii, K. (1997) · Anesthesiology · doi:10.1097/00000542-199709000-00005 · Cited by 1,090
α2-Adrenergic Agonists for Regional Anesthesia: A Clinical Review of Clonidine (1984 - 1995)
Eisenach, J. C., De Kock, M., & Klimscha, W. (1996) · Anesthesiology · doi:10.1097/00000542-199609000-00026 · Cited by 888
Yaksh, T. L., & Ramana Reddy, S. V. (1981) · Anesthesiology · doi:10.1097/00000542-198106000-00004 · Cited by 516
Nerve Injury Associated with Anesthesia
Kroll, D. A., Caplan, R. A., Posner, K., Ward, R. J., & Cheney, F. W. (1990) · Anesthesiology · doi:10.1097/00000542-199008000-00002 · Cited by 354
Neurologic Deficits following Epidural or Spinal Anesthesia
Kane, R. E. (1981) · Anesthesia & Analgesia · doi:10.1213/00000539-198103000-00006 · Cited by 338
Spinal cord pharmacology of pain
Dickenson, A. H. (1995) · British Journal of Anaesthesia · doi:10.1093/bja/75.2.193 · Cited by 318
Transient Neurologic Symptoms After Spinal Anesthesia
Hampl, K. F., Schneider, M. C., Ummenhofer, W., & Drewe, J. (1995) · Anesthesia & Analgesia · doi:10.1097/00000539-199512000-00006 · Cited by 303
Malmberg, A. B., & Yaksh, T. L. (1993) · Anesthesiology · doi:10.1097/00000542-199308000-00012 · Cited by 269
Phase I Safety Assessment of Intrathecal Neostigmine Methylsulfate in Humans
Hood, D. D., Eisenach, J. C., & Tuttle, R. (1995) · Anesthesiology · doi:10.1097/00000542-199502000-00003 · Cited by 265
Dripps, R. D. (1954) · Journal of the American Medical Association · doi:10.1001/jama.1954.02950160016005 · Cited by 265
Cited by
Ketamine: A Review of Clinical Pharmacokinetics and Pharmacodynamics in Anesthesia and Pain Therapy
Peltoniemi, M. A., Hagelberg, N. M., Olkkola, K. T., & Saari, T. I. (2016) · Clinical Pharmacokinetics · doi:10.1007/s40262-016-0383-6 · Cited by 672
Abdallah, F. W., & Brull, R. (2013) · British Journal of Anaesthesia · doi:10.1093/bja/aet066 · Cited by 347
Intrathecal Methylprednisolone for Intractable Postherpetic Neuralgia
Kotani, N., Kushikata, T., Hashimoto, H., Kimura, F., Muraoka, M., Yodono, M., Asai, M., & Matsuki, A. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011233432102 · Cited by 310
The role of ketamine in pain management
Visser, E., & Schug, S. A. (2006) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2006.06.021 · Cited by 256
Metadata
- Authors
- Hodgson, P. S., Neal, J. M., Pollock, J. E., & Liu, S. S.
- Venue
- Anesthesia & Analgesia
- Published
- 1999-04
- Volume
- 88
- Issue
- 4
- Pages
- 797-809
- ISSN
- 0003-2999 (ISSN-L)
- OpenAlex
- W2090823918
- Cited by
- 283
- References
- 29
- FWCI
- 14.27
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Neurotoxicity of Drugs Given Intrathecally (Spinal). https://app.cochat.ai/papers/10.1097/00000539-199904000-00023
- The paper
- Hodgson, P. S., Neal, J. M., Pollock, J. E., & Liu, S. S. (1999). The Neurotoxicity of Drugs Given Intrathecally (Spinal). Anesthesia & Analgesia. https://doi.org/10.1097/00000539-199904000-00023
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.